AtaCor EV-ICD Lead System
Prevention of Sudden Cardiac Death (Ventricular Fibrillation/Tachycardia)
Feasibility / Early ClinicalIn Development
Key Facts
Indication
Prevention of Sudden Cardiac Death (Ventricular Fibrillation/Tachycardia)
Phase
Feasibility / Early Clinical
Status
In Development
Company
About AtaCor Medical
AtaCor Medical is committed to transforming cardiac rhythm management by developing extravascular lead and deployment systems that preserve the integrity of the heart and vasculature. The company's core innovation is a parasternal lead system designed to work with commercially available ICDs, offering a potentially safer alternative to transvenous and subcutaneous ICDs. Led by a seasoned team with deep experience in cardiac rhythm management, including veterans from the S-ICD development, AtaCor is backed by a syndicate of leading life science venture capital firms and is advancing its technology through clinical development.
View full company profile